ALK and non-small cell lung carcinoma: The clinical trials of ASCEND series demonstrated that ceritinib was significantly superior to chemotherapy (median PFS, 5.4 months vs. 1.6 months) in patients with advanced ALK‐positive NSCLC resistant to crizotinib treatment and had a good safety profile.6, 7